Malignant thymoma (MT) is a rare tumor that is often associated with myasthenia gravis (MG). This tumor is considered resistant to chemotherapy. We had the opportunity to treat five patients with MT with cyclophosphamide 800 mg/m2, Adriamycin 50 mg/m2, and vincristine 1.4 mg/m2 (CAV) in cycles of 21
Invasive thymoma with myasthenia gravis
β Scribed by Yasumasa Monden; Kazuya Nakahara; Satoru Nanjo; Yoshitaka Fujii; Akihide Matsumura; Akira Masaoka; Yasunaru Kawashima
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 516 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
We report the first case of stiff-persons' (-man) syndrome in the setting of a histologically proven thymoma. Muscular hyperactivity was abolished under general anesthesia and the symptoms of stiffness resolved after thymectomy and three courses of intravenous immunoglobulins. After thymectomy, the
## Abstract Myotonic dystrophy type 1 (DM1) is an autosomalβdominant multisystemic disorder that may rarely be associated with benign and malignant neoplasms. Cases of both thymoma and myasthenia gravis in association with DM1 are extremely rare. A literature review revealed only three prior report